After cancer treatment ends, many patients find that “appetite just doesn’t come back”:
food looks unappealing, a few bites feel filling, or even the smell triggers nausea.
This is not due to “lack of effort” — it is the result of treatment affecting multiple body systems and temporarily disrupting appetite regulation.
Understanding these common causes can reduce self-blame and open the door to more targeted ways to improve.
Walking through this valley together with the gentlest care
When a family member is diagnosed with cancer, you may notice they no longer laugh as easily, talk less, sleep poorly, or sometimes fall silent or tear up unexpectedly.
These low moods are completely normal — they are not only facing the illness itself, but also the uncertainty, loss of control, and guilt towards family.
As a caregiver, your role is not to “force them to cheer up”, but to let them know: their feelings are seen, accepted, and allowed to exist.
Cancer-related fatigue (CRF) after chemotherapy is experienced by more than 70–90 % of patients.
It is not ordinary tiredness — sleeping more does not fully resolve it, because it involves disrupted mitochondrial function, high oxidative stress, persistent low-grade inflammation, nutrient depletion, and hormonal changes working together.
Let you clearly know “how your immunity is right now” — no longer just a feeling
Many cancer patients, after treatment or during long-term follow-up, most often ask:
“Has my immunity recovered yet?”
Conventional blood tests showing white blood cell or lymphocyte counts can only tell you “normal” or “low”,
but cannot reveal the overall “fighting strength” of your immune system at this moment.
Clearing up doubts about circulating tumour cell (CTC) monitoring
RGCC cancer monitoring tests (OncoTrace, Onco-D-clare, Onconomics Plus®, etc.) have become valuable supportive tools for many patients during post-surgical follow-up, active treatment, or long-term surveillance.
In the field of modern oncology, early detection and personalized treatment have become key to improving survival rates and quality of life for patients. RGCC (Research Genetic Cancer Centre) testing is a series of advanced blood-based assays that require only a single blood draw to analyze circulating tumor cells (CTCs) and related biomarkers. These tests provide critical insights into the presence, progression, and treatment response of cancer, helping physicians create truly tailored treatment plans. The three most commonly used tests—Oncotrace, Onco-D-clare, and Onconomics Plus—excel in monitoring, screening, and treatment optimization, respectively.
A cancer diagnosis often brings immense physical and emotional burdens. Beyond the disease itself, treatments such as chemotherapy and radiotherapy frequently cause side effects including pain, fatigue, loss of appetite, nausea, sleep disturbances, and emotional distress. These symptoms not only affect quality of life but can also interfere with primary cancer treatments. Palliative Support Care is a patient-centered, comprehensive approach designed to intervene from the early stages of diagnosis, alleviating symptoms and improving overall well-being, enabling patients to maintain comfort, dignity, and autonomy throughout their treatment journey.
RGCC OncoTrace is one of the most advanced circulating tumour cell (CTC) detection and monitoring technologies available internationally. With a single blood draw, it can capture cancer cells that have “escaped” the tumour and are circulating in the blood, providing key information on quantity, phenotype, and activity. This allows physicians to detect changes before tumour markers rise or imaging shows any alteration.
Surgery is complete and the tumour has been removed —
many believe the hardest part is over.
But for most patients, the real challenge begins in the postoperative phase:
How to heal wounds faster? When will fatigue finally lift?
How to monitor recurrence risk? Can quality of life return to normal?
When cancer treatment — especially haematological malignancies, bone-marrow transplantation, long-term corticosteroids, or rituximab —
drives the immune system into “low-battery mode”,
the most common consequences are:
colds that drag on for weeks, recurrent pneumonia, shingles covering half the body, wounds that refuse to heal…